Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature

Anna Ferrazzi, Irene Russo, Giulia Pasello, Mauro Alaibac

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Gefitinib is a selective epidermal growth factor receptor tyrosine kinase inhibitor utilized for the treatment of advanced non-small cell lung carcinoma. The most commonly reported adverse event during gefitinib therapy is skin rash, particularly a papulopustular acne‑like eruption. Cutaneous toxicities can affect treatment compliance and the quality of life of the patient. The present study reports a case of gefitinib‑induced atypical skin reaction in a 73‑year‑old woman with advanced non‑small cell lung cancer, who developed a squamous‑crusted eruption on her face after 4 weeks of oral treatment with gefitinib at a dose of 250 mg/day. The patient was treated with 100 mg minocyclin (2 tablets/day, orally) and with ryfamicin topically. A complete resolution of the lesions was observed 2 weeks later. The present case report explored the pathogenesis of this skin manifestation, focusing on the underlying immunological mechanisms. A review of the literature concerning skin reactions to gefitinib was also conducted.

Original languageEnglish
Pages (from-to)197-200
Number of pages4
JournalExperimental and Therapeutic Medicine
Volume11
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Lung Neoplasms
Skin
Non-Small Cell Lung Carcinoma
Skin Manifestations
Therapeutics
Exanthema
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Tablets
Quality of Life
gefitinib

Keywords

  • Epidermal growth factor receptor
  • Gefitinib
  • Skin immune system

ASJC Scopus subject areas

  • Medicine(all)
  • Cancer Research
  • Immunology and Microbiology (miscellaneous)

Cite this

Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer : A case report and review of the literature. / Ferrazzi, Anna; Russo, Irene; Pasello, Giulia; Alaibac, Mauro.

In: Experimental and Therapeutic Medicine, Vol. 11, No. 1, 01.01.2016, p. 197-200.

Research output: Contribution to journalArticle

@article{e370a26f3bb945f781ae8df24b2367c0,
title = "Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature",
abstract = "Gefitinib is a selective epidermal growth factor receptor tyrosine kinase inhibitor utilized for the treatment of advanced non-small cell lung carcinoma. The most commonly reported adverse event during gefitinib therapy is skin rash, particularly a papulopustular acne‑like eruption. Cutaneous toxicities can affect treatment compliance and the quality of life of the patient. The present study reports a case of gefitinib‑induced atypical skin reaction in a 73‑year‑old woman with advanced non‑small cell lung cancer, who developed a squamous‑crusted eruption on her face after 4 weeks of oral treatment with gefitinib at a dose of 250 mg/day. The patient was treated with 100 mg minocyclin (2 tablets/day, orally) and with ryfamicin topically. A complete resolution of the lesions was observed 2 weeks later. The present case report explored the pathogenesis of this skin manifestation, focusing on the underlying immunological mechanisms. A review of the literature concerning skin reactions to gefitinib was also conducted.",
keywords = "Epidermal growth factor receptor, Gefitinib, Skin immune system",
author = "Anna Ferrazzi and Irene Russo and Giulia Pasello and Mauro Alaibac",
year = "2016",
month = "1",
day = "1",
doi = "10.3892/etm.2015.2881",
language = "English",
volume = "11",
pages = "197--200",
journal = "Experimental and Therapeutic Medicine",
issn = "1792-0981",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer

T2 - A case report and review of the literature

AU - Ferrazzi, Anna

AU - Russo, Irene

AU - Pasello, Giulia

AU - Alaibac, Mauro

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Gefitinib is a selective epidermal growth factor receptor tyrosine kinase inhibitor utilized for the treatment of advanced non-small cell lung carcinoma. The most commonly reported adverse event during gefitinib therapy is skin rash, particularly a papulopustular acne‑like eruption. Cutaneous toxicities can affect treatment compliance and the quality of life of the patient. The present study reports a case of gefitinib‑induced atypical skin reaction in a 73‑year‑old woman with advanced non‑small cell lung cancer, who developed a squamous‑crusted eruption on her face after 4 weeks of oral treatment with gefitinib at a dose of 250 mg/day. The patient was treated with 100 mg minocyclin (2 tablets/day, orally) and with ryfamicin topically. A complete resolution of the lesions was observed 2 weeks later. The present case report explored the pathogenesis of this skin manifestation, focusing on the underlying immunological mechanisms. A review of the literature concerning skin reactions to gefitinib was also conducted.

AB - Gefitinib is a selective epidermal growth factor receptor tyrosine kinase inhibitor utilized for the treatment of advanced non-small cell lung carcinoma. The most commonly reported adverse event during gefitinib therapy is skin rash, particularly a papulopustular acne‑like eruption. Cutaneous toxicities can affect treatment compliance and the quality of life of the patient. The present study reports a case of gefitinib‑induced atypical skin reaction in a 73‑year‑old woman with advanced non‑small cell lung cancer, who developed a squamous‑crusted eruption on her face after 4 weeks of oral treatment with gefitinib at a dose of 250 mg/day. The patient was treated with 100 mg minocyclin (2 tablets/day, orally) and with ryfamicin topically. A complete resolution of the lesions was observed 2 weeks later. The present case report explored the pathogenesis of this skin manifestation, focusing on the underlying immunological mechanisms. A review of the literature concerning skin reactions to gefitinib was also conducted.

KW - Epidermal growth factor receptor

KW - Gefitinib

KW - Skin immune system

UR - http://www.scopus.com/inward/record.url?scp=84949448591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949448591&partnerID=8YFLogxK

U2 - 10.3892/etm.2015.2881

DO - 10.3892/etm.2015.2881

M3 - Article

AN - SCOPUS:84949448591

VL - 11

SP - 197

EP - 200

JO - Experimental and Therapeutic Medicine

JF - Experimental and Therapeutic Medicine

SN - 1792-0981

IS - 1

ER -